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Abstract
Objectives: The ovarian tumor marker CA125 is expressed on human MUC16, a cell surface bound mucin that is also shed by
proteolytic cleavage. Human MUC16 is overexpressed by ovarian cancer cells. MUC16 facilitates the binding of ovarian tumor
cells to mesothelial cells lining the peritoneal cavity. Additionally, MUC16 also is a potent inhibitor of natural killer cell mediated
anti-tumor cytotoxic responses. Extensive studies using human as well as murine ovarian tumor cell models are required to
clearly define the function of MUC16 in the progression of ovarian tumors. The major objective of this study was to determine
if the murine ovarian tumor cells, MOVCAR, express Muc16 and to characterize antibodies that recognize this mucin.
Methods: RT-PCR analysis was used for detecting the Muc16 message and size exclusion column chromatography for isolating
Muc16 produced by MOVCAR cells. Soluble and cell-associated murine Muc16 were analyzed, respectively, by Western blotting
and flow cytometry assays using a new panel of antibodies. The presence of N-linked oligosaccharides on murine Muc16 was
determined by ConA chromatography.
Results: We demonstrate that murine Muc16 is expressed by mouse ovarian cancer cells as an ~250 kDa glycoprotein that
carries both O-linked and N-linked oligosaccharides. In contrast to human MUC16, the murine ortholog is primarily released
from the cells and cannot be detected on the cell surface. Since the released murine Muc16 is not detected by conventional anti-
CA125 assays, we have for the first time identified a panel of anti-human MUC16 antibodies that also recognizes the murine
counterpart.
Conclusion: The antibodies identified in this study can be used in future purification of murine Muc16 and exhaustive study of
its properties. Furthermore, the initial identification and characterization of murine Muc16 is a vital preliminary step in the
development of effective murine models of human ovarian cancer. These models will aid in the further elucidation of the role
that human MUC16 plays in the etiology and progression of ovarian tumors.
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Background
Epithelial ovarian cancer (EOC) is the fifth leading cause
of all female cancer-related deaths in the western world
[1]. Despite its prevalence, this disease is marked by diffi-
culties in early diagnosis as well as lack of an effective
screening test. The major marker of human EOC is the
CA125 peptide epitope, serum levels of which are elevated
in EOC patients [2]. The CA125 epitope is contained in
MUC16, a 2–5 million Da transmembrane mucin that is
over expressed in EOC [3,4]. As a shed type of mucin,
MUC16 is both expressed on the cell surface and released
following proteolytic cleavage into the extracellular space
[5].
Recent studies indicate that MUC16 is not only important
as a tumor marker but also promotes peritoneal metasta-
sis of ovarian cancer and suppresses the cytolytic
responses of human natural killer cells [6,7]. The physio-
logical function of this mucin is not known; however, its
biochemical properties have constrained studies on this
molecule. The high molecular weight of MUC16 requires
the use of extensive molecular biological approaches to
study the importance of this mucin in the pathogenesis of
ovarian cancer. In addition, a thorough study of MUC16
expressed in mouse models for ovarian cancer will also
aid in understanding its physiological roles.
Recently, several murine ovarian tumor models have been
developed [8-10]. In one particular model, transgenic
mice were generated expressing the SV40 T-antigen under
the direct influence of the Mullerian inhibitory substance
(an ovary-specific gene), and the mice spontaneously
developed ovarian cancers resembling poorly differenti-
ated ovarian adenocarcinomas in women [8,11]. Murine
ovarian tumor cell lines, designated as MOVCAR, have
been generated from these tumors [8]. These cell lines
provided us an opportunity to perform biochemical and
physiological studies on the murine counterpart of
MUC16, designated as Muc16. Here we report the expres-
sion and initial biochemical characterization of Muc16
expressed by the MOVCAR cells. Specifically, we identify
expression of Muc16 mRNA and provide evidence that,
unlike MUC16, the murine ortholog is not expressed on
the cell surface but is instead primarily released from the
MOVCAR cells. In addition, we have for the first time
identified specific monoclonal antibodies that can be
used in future studies of murine Muc16.
Methods
Cells, antibodies, and other reagents
The anti-MUC16 antibody VK8 [12] was a kind gift from
Beatrice Yin (Memorial Sloan Kettering, New York, USA).
The panel of anti-MUC16 mouse monoclonal antibodies
was generated against human ascites derived MUC16
using the ABL-MYC transformation technology [13,14].
The four murine ovarian cancer cell lines–MOVCAR 1, 2,
9, and 10–were kindly provided by Dr. Denise Connolly
(Fox Chase Cancer Center, Philadelphia) and cultured in
DMEM supplemented with 10% FBS, 0.2% ITS and 1%
antibiotic-antimycotic. The human epithelial ovarian
tumor cell lines OVCAR-3, SKOV-3, and CAOV-3 were
purchased from ATCC.
RT-PCR
Total RNA was isolated from MOVCAR cell lines using the
Qiagen RNeasy® Mini kit and 2 μg of total RNA was reverse
transcribed. PCR reactions were performed with 2.5 μL of
cDNA. For each sample, a control tube containing all rea-
gents except template cDNA was prepared. cDNA was
amplified with the following primer pairs from Integrated
DNA Technologies: Muc16 5'-TGCCACCTACCAGTT-
GAAAG-3' and 5'-GTACCGCCAAGCAGATGAG-3';
GAPDH 5'-TGCTGAGTATGTCGTGGAGTCTA-3' and 5'-
AGTGGGAGTTGCTGTTGAAGTCG-3'. The amplified
Muc16 cDNA from MOVCAR-2 cells was sequenced at the
University of Wisconsin-Madison Biotechnology Center.
Flow cytometry
Cells (2.5 × 105) were fixed with 2% paraformaldehyde,
washed three times with sterile filtered PBS/1% BSA (PBS-
BSA), and permeabilized with 0.1% Triton X-100 on ice.
Unfixed cells (2.5 × 105) were kept on ice during this time.
All cells were incubated with primary and secondary anti-
bodies for 30 minutes on ice. The 618F and 653F antibod-
ies were used at 1:250 dilutions in PBS-BSA. VK8 from cell
culture supernatant was used directly for labeling. The
FITC-conjugated goat anti-mouse (GAM) IgG, Fc specific
secondary antibody (Jackson ImmunoResearch) was used
for detection at 1:100.
Protein isolation, electrophoresis, and Western blotting
Soluble Muc16 was isolated from MOVCAR-2 serum-free
spent media which was concentrated 20-fold. Approxi-
mately 5 mL of concentrated media was loaded onto a
Sepharose-CL4B (Sigma) column (1.5 cm × 42 cm) pre-
equilibrated with 10 mM ammonium bicarbonate buffer
and 1 mL collected fractions were monitored for absorb-
ance at 280 nm. The desired fractions were pooled and
lyophilized. Soluble human MUC16 was isolated as
described in our previous study [15]. Cell lysates were pre-
pared by treating the ovarian tumor cells with Tris buff-
ered saline containing 0.5% Triton X-100 and a cocktail of
protease inhibitors (Sigma).
For Western blotting, 25 μg of protein was separated on
7.5% SDS-PAGE gels and electroblotted on a PVDF mem-
brane. The membranes were sequentially overlaid with
anti-human MUC16 antibodies followed by horseradish
peroxidase labeled GAM IgG (Pierce; 1:20,000 dilution).
Signals were detected by using the West Pico kit (Pierce).Journal of Ovarian Research 2009, 2:8 http://www.ovarianresearch.com/content/2/1/8
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Coomassie Blue and silver staining of gels was performed
using protocols established in our laboratory.
ConA Chromatography
Concentrated harvest media from MOVCAR-2 cells con-
taining 22 mg of total protein was loaded onto a 5 mL
Concanavalin A (ConA) column (Sigma; ConA immobi-
lized on 4% cross-linked agarose) equilibrated in 1×
ConA buffer (100 mM Tris HCl containing 1.5 M sodium
chloride, 10 mM calcium chloride, 10 mM magnesium
chloride, and 0.2% sodium azide). The column was
eluted with ConA buffer and fractions were monitored for
absorbance at 280 nm. The bound glycoproteins were
eluted by washing with a step gradient (100, 250, and 500
mM) of α-methylmannopyranoside (α-Me-Man). Frac-
tions from eluted peaks were pooled, and the proteins
were analyzed by Western blotting.
Results
Expression of Muc16 mRNA in MOVCAR cells
We first conducted RT-PCR experiments to determine
expression of Muc16 by the MOVCAR cells. Specific prim-
ers for Muc16 were designed around the unique domain
which was identified based on its percent identity with the
corresponding region of MUC16. The region between
25605 bp to 26125 bp of the Muc16 sequence reported in
GenBank accession no. XM_911929.2 was amplified by
these primers. Muc16 mRNA was expressed in each of the
four MOVCAR cell lines tested by RT-PCR (Fig. 1). After
DNA sequencing, the PCR product from the MOVCAR-2
cell line was found to have 99% identity with the pro-
jected sequence of Muc16. Although Muc16 was always
expressed in these cells, the level of Muc16 mRNA varied
in different passages (data not shown).
Detection of Soluble Muc16 in MOVCAR media
Soluble MUC16 is shed into the spent harvest media of
the human epithelial ovarian tumor cell line, OVCAR-3.
The shed MUC16 can be isolated from the media follow-
ing concentration and separation by size exclusion chro-
matography [15]. We therefore determined if Muc16 was
present in the spent media from MOVCAR-2 cells.
We consistently found that the MOVCAR-2 media purifi-
cation profiles on a Sepharose CL-4B size exclusion col-
umn followed the same pattern as the OVCAR-3 media
profiles (Fig. 2) [15]. The murine Muc16 was only slightly
retarded on this column (Fig. 2) and was initially identi-
fied (data not shown) by Alcian Blue staining [16].
To specifically identify Muc16, we conducted Western
blot analysis of Pool 1 using MUC16 specific VK8 and
OC125 antibodies. No bands for Muc16 were detected in
these analyses. The widely employed clinical serum
CA125 assay was also unable to detect CA125 in spent
media of MOVCAR-2 cells. We therefore tested a panel of
ten anti-MUC16 antibodies that we recently generated
using the novel ABL-MYC technology. All of these anti-
bodies were able to detect an approximately 250 kDa
band for Muc16 (Fig. 3). The binding to Muc16 was
weaker as compared to MUC16 and was usually observed
at 1:250 dilution of the primary antibodies.
618F and 653F specifically recognize human MUC16
Two antibodies from the panel that efficiently recognized
Muc16 by Western blotting were 618F and 653F. When a
purified preparation of human MUC16 was analyzed by
Western blotting, the 618F antibody exhibited a similar
RT-PCR verification of Muc16 mRNA expression in four  MOVCAR cell lines Figure 1
RT-PCR verification of Muc16 mRNA expression in 
four MOVCAR cell lines. GAPDH gene was used as a 
housekeeping control.
Muc16 
(520 bp)
GAPDH 
(602 bp)
MOVCAR 1
MOVCAR 2
MOVCAR 9
MOVCAR 10
Purification of Soluble Muc16 on a Sepharose CL-4B Column Figure 2
Purification of Soluble Muc16 on a Sepharose CL-4B 
Column. Concentrated MOVCAR-2 spent media was sepa-
rated as described in Methods. Fractions located under the 
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banding pattern to that shown by the VK-8 antibody (Fig.
4A). Using flow cytometry we also demonstrated that
both 618F and 653F specifically bind to the OVCAR-3 but
not to the MUC16neg SKOV-3 or CAOV-3 cells (Fig. 4B).
The binding of 618F, 653F and VK-8 to the OVCAR-3,
SKOV-3, and CAOV-3 cells was comparable. Considering
the demonstrable specificity of 618F and 653F for MUC16
and their ability to recognize Muc16 from the MOVCAR-
2 spent media, we primarily conducted all of our further
experiments with these two antibodies.
Binding of murine muc16 to the Lectin ConA
Although mucins are known to express high amounts of
O-glycans, MUC16 also carries a significant proportion of
N-linked oligosaccharides. To determine if Muc16 also
expresses N-linked glycans, we loaded the concentrated
spent media from MOVCAR-2 cells on a ConA column.
The flow-through fractions from the column were col-
lected and the retained material was eluted using sequen-
tial washes containing increasing concentrations of α-Me-
Man (Fig. 5a). Muc16 was detected in all of the α-Me-Man
fractions but not in the flow-through pool by Western
blot analysis using the 653F antibody (Fig. 5b).
Murine muc16 is not expressed on the MOVCAR cell 
surface
Having identified soluble forms of Muc16 by Western
blotting, we investigated whether this mucin was also
expressed on the cell surface of MOVCAR cells. We con-
sistently found little to no extracellular Muc16 expression
on the MOVCAR-10 cells when the expression of this
mucin was determined by flow cytometry using the 618F
antibody (Fig. 6a). On the other hand, high levels of intra-
cellular Muc16 were detected in the MOVCAR-10 cells
using the 618F antibody (Fig. 6b). These results are in
sharp contrast with the intense extracellular binding of
this antibody found on OVCAR-3 cells (Fig. 4b).
Correcting for background fluorescence of the isotype
control, our results for all MOVCAR cell lines showed a
clear expression of intracellular Muc16 and only minimal
presence of Muc16 on the cell surface (Figs. 6a–d). Similar
results were obtained with both the 618F and 653F anti-
bodies (Fig. 6c and 6d).
Discussion
We have identified soluble and cell-associated Muc16 in
MOVCAR cells. While soluble MUC16 is over 3 million
Da, Western blots indicate that the murine counterpart is
significantly smaller, at approximately 250 kDa. With its
tertiary structure intact during size exclusion chromatog-
raphy, however, Muc16 behaves as a much larger protein.
This suggests intermolecular crosslinking in Muc16 simi-
lar to that observed in other mucins. Extensive glycosyla-
tion of Muc16 arising from the presence of O-linked and
Identification of soluble Muc16 and MUC16 by Western blot- ting Figure 3
Identification of soluble Muc16 and MUC16 by West-
ern blotting. Purified MUC16 (25 μg total protein/lane) 
from MOVCAR-2 (lane 1) and OVCAR-3 cells (lane 2) was 
electrophoresed by SDS-PAGE and probed with a panel of 
anti-MUC16 monoclonal antibodies. Arrows indicate migra-
tion of 250 kDa molecular weight marker and identity of 
antibody used is shown on the right of each blot.Journal of Ovarian Research 2009, 2:8 http://www.ovarianresearch.com/content/2/1/8
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Specificity of 618F for human MUC16 Figure 4
Specificity of 618F for human MUC16. (A) Purity of 
human MUC16 isolated from spent media of OVCAR-3 cells 
as determined by Coomassie Blue (1) and silver staining (2) 
of SDS-PAGE gel. Western blot analysis of the purified 
human MUC16 was conducted using the 618F (3) and the 
VK-8 (4) antibodies. (B) MUC16 expression on OVCAR-3, 
CAOV-3, and SKOV-3 was determined by flow cytometry 
using 653F, 618F, or VK-8 as the primary antibodies. Mean 
fluorescence intensity of the corresponding isotype controls 
was subtracted in each case. Data shown is mean of two 
independent experiments. Note that the binding of 618F, 
653F and VK-8 to these three cell lines is comparable.
Binding of murine Muc16 to the lectin ConA Figure 5
Binding of murine Muc16 to the lectin ConA. (A) Con-
centrated MOVCAR-2 spent media was separated on a 
ConA affinity column. Fractions eluted with ConA buffer 
were combined in pools 1 and 2. Fractions eluted with 100, 
250, and 500 mM α-Me-Man concentrations were combined 
in pools 3–5, respectively. (B) Pooled fractions were electro-
phoresed by SDS-PAGE and probed with 653F. The arrow 
indicates migration of 250 kDa molecular weight marker. 
Murine Muc16 was detected primarily in pools 3–5.
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N-linked oligosaccharides, as demonstrated in our stud-
ies, may also contribute to its large tertiary structure.
Given the lack of cell surface Muc16 on MOVCAR cells, we
can make important distinctions between the human and
murine forms of the mucin. MUC16 is both expressed on
the cell surface and shed from the cell in soluble forms.
Muc16, on the other hand, is detected primarily in the
spent media and in the intracellular environment. This
observation indicates that the Muc16 is either rapidly
cleaved from the cell surface by a very active proteolytic
enzyme or is an alternatively spliced form that is primarily
secreted by the MOVCAR cells. Our future studies will
focus on deciphering the mechanisms that lead to the gen-
eration of the shed Muc16.
The shed and cell surface bound MUC16 play important
roles in the progression of human ovarian tumors. While
the shed MUC16 appears to have major influence on the
cytolytic function of natural killer cells, the cell surface
bound MUC16 is important for binding of the ovarian
tumor cells to the mesothelial cells that line the peritoneal
cavity. Since the MOVCAR cells shed Muc16, this murine
model may be important in understanding the immu-
nomodulatory roles of this mucin. The shed Muc16
should also be found in the serum of mice bearing the
Extra-and intracellular Muc16 expression by MOVCAR cells Figure 6
Extra-and intracellular Muc16 expression by MOVCAR cells. (A) MOVCAR-10 cells were labeled with 618F (grey line) 
and analyzed for cell surface expression of Muc16 by flow cytometry. Isotype control is shown by dark line. (B) MOVCAR-10 
cells were fixed and expression of intracellular Muc16 was detected by using the 618F antibody (grey line). Dark line shows iso-
type control. (C) Expression of cell surface and intracellular Muc16 in the four MOVCAR cell lines was determined by flow 
cytometry using the 618 F antibody. The mean fluorescence intensity for the binding of 618F to the cell surface and intracellu-
lar Muc16 is plotted after subtracting the mean fluorescence intensity for the matched isotype controls. Each measurement is a 
mean of two independent experiments. (D) Same as in (C) except 653F was used for detection of murine Muc16.
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MOVCAR tumors. The antibodies identified in the current
study can therefore be used to monitor tumor progression
in mice. These antibodies can also be used to purify
Muc16 so that its biochemical and biological properties
can be exhaustively studied.
Conclusion
In this study we demonstrate that Muc16 is expressed by
murine ovarian tumor cells and can be detected by newly
developed murine monoclonal antibodies that were ini-
tially generated against human MUC16.
List of abbreviations
EOC: epithelial ovarian cancer; ConA: Concanavalin A; α-
Me-Man: α-methylmannopyranoside.
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